Neuropsychiatric symptoms in Parkinson's disease

Movement Disorders

Volumn 24, Issue 15, 2009, Pages 2175-2186

  Aarsland, Dag ^a,b,c   Marsh, Laura ^d   Schrag, Anette ^e  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anxiety; Apathy; Depression; Hallucinations; Parkinson's disease

Indexed keywords

AMITRIPTYLINE; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; DESIPRAMINE; DOPAMINE RECEPTOR; LEVODOPA; METHYLPHENIDATE; MIRTAZAPINE; MONOAMINE OXIDASE A INHIBITOR; NORTRIPTYLINE; OXYBATE SODIUM; PAROXETINE; PLACEBO; PRAMIPEXOLE; REBOXETINE; ROPINIROLE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VENLAFAXINE;

ANXIETY DISORDER; APATHY; BIPOLAR DEPRESSION; CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG INDICATION; EPIDEMIOLOGICAL DATA; FATIGUE; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; NEUROPSYCHIATRIC SYMPTOMS; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; REVIEW; TREATMENT RESPONSE; VISUAL HALLUCINATION;

ANXIETY; DEPRESSION; FATIGUE; HUMANS; MENTAL DISORDERS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE;

EID: 72849115874     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22589     Document Type: Review

References (94)

1. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:492-496. (Pubitemid 29438205)
2. Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson's disease? Psychol Med 2001;31:65-73.
3. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23:183-189. (Pubitemid 351311545)
4. Starkstein SE, Leentjens AFG. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry 2008;79: 1088-1092.
5. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol 2003;16:178-183. (Pubitemid 37409029)
6. Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993;34:465-470. (Pubitemid 23337729)
7. Richard IH. Anxiety disorders in Parkinson's disease. Adv Neurol 2005;96:42-55.
8. Leentjens AF, Dujardin K, Marsh L, et al. Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2008;23:2015-2025.
9. Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990;147: 217-220. (Pubitemid 20060479)
10. Nuti A, Ceravolo R, Piccinni A, et al. Psychiatric comorbidity in a population of Parkinson's disease patients. EurJ Neurol 2004;11:315-320. (Pubitemid 38903564)
11. Lauterbach EC, Freeman A, Vogel RL. Differential DSM-III psychiatric disorder prevalence profiles in dystonia and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2004;16:29-36. (Pubitemid 38233360)
12. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59: 408-413. (Pubitemid 34857934)
13. Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD. Mood swings associated with the on-off phenomenon in Parkinson's disease. Psychol Med 1987;17: 899-904. (Pubitemid 17166561)
14. Siemers ER, Shekhar A, Quaid K, Dickson H. Anxiety and motor performance in Parkinson's disease. Mov Disord 1993;8: 501-506. (Pubitemid 23291206)
15. Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 1995;45:1757-1760.
16. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 2006;113:211-220. (Pubitemid 43382593)
17. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134. (Pubitemid 39362633)
18. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50:743-755.
19. Mayeux R. The "serotonin hypothesis" for depression in Parkinson's disease. Adv Neurol 1990;53:163-166.
20. Torack RM, Morris JC. The association of ventral tegmental area histopathology with adult dementia. Arch Neurol 1988;45:497-501.
21. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128:1314-1322. (Pubitemid 40826185)
22. Arabia G, Grossardt BR, Geda YE, et al. Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson disease. Arch Gen Psychiatry 2007;64:1385-1392. (Pubitemid 350223556)
23. Myslobodsky M, Lalonde FM, L HI. Are patients with Parkinson's disease suicidal? J Geriatr Psychiatry Neurol 2001;14:120-124.
24. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986;49:381-389 (Pubitemid 16108903)
25. Myslobodsky M, Lalonde FM, Hicks L. Are patients with Parkinson's disease suicidal? J Geriatr Psychiatry Neurol 2001;14:120-124.
26. Moriarty J. Suicide following deep brain stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry 2008;79:851.
27. Soulas T, Gurruchaga JM, Palfi S, Cesaro P, Nguyen JP, Fenelon G. Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry 2008;79:952-954.
28. Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008;131:2720-2728.
29. Nazem S, Siderowf AD, Duda JE, et al. Suicidal and death ideation in Parkinson's disease. Mov Disord 2008;23:1573-1579.
30. Mondolo F, Jahanshahi M, Grana A, Biasutti E, Cacciatori E, Di Benedetto P. Evaluation of anxiety in Parkinson's disease with some commonly used rating scales. Neurol Sci 2007;28:270-275. (Pubitemid 350055437)
31. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM IV). Washington, DC: American Psychiatric Association; 1994.
32. Marsh LF, McDonald WM, Fau Cummings J, Cummings JF, Ravina B. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006;21:148-158.
33. Starkstein SE, Merello M, Jorge R, et al. A validation study of depressive syndromes in Parkinson's disease. Mov Disord 2008;23:538-546.
34. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-1192. (Pubitemid 47067217)
35. Cole K, Vaughan FL. The feasibililty of using cognitive behavior therapy for depression associated with Parkinson's disease: a literature review. Parkinsonism Relat Disord 2005;11:269-276. (Pubitemid 40982501)
36. Frisina PG, Tenenbaum HR, Borod JC, Foldi NS. The effects of antidepressants in Parkinson's disease: a meta-analysis. Int J Neurosci 2008;118:667-682. (Pubitemid 351630874)
37. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the quality standards subcommittee of the American academy of neurology. Neurology 2002;58:11-17. (Pubitemid 34041931)
38. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005;20:1161-1169. (Pubitemid 41632203)
39. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108-11105 (Pubitemid 46559844)
40. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002. (Pubitemid 44044781)
41. Morgan JC, Menza M. A controlled trial of antidepressants in patients with Parkinson disease and depression. Curr Neurol Neurosci Rep 2009;9:263-265.
42. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008;23:850-857.
43. Voon V, Lang AE. Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. Clin Neuropharmacol 2004;27:90-92. (Pubitemid 38569182)
44. Straits-Troster K, Fields JA, Wilkinson SB, et al. Health-related quality of life in Parkinson's disease after pallidotomy and deep brain stimulation. Brain Cogn 2000;42:399-416. (Pubitemid 30210933)
45. de Beurs E, Wilson KA, Chambless DL, Goldstein AJ, Feske U. Convergent and divergent validity of the Beck anxiety inventory for patients with panic disorder and agoraphobia. Depress Anxiety 1997;6:140-146. (Pubitemid 28164817)
46. da Silva TM, Munhoz RP, Alvarez C, et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 2008;111:351-359.
47. Paus S, Schmitz-Hubsch T, Wullner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson's disease: a pilot study. Mov Disord 2007;22:1495-1498. (Pubitemid 47280641)
48. Cardoso EF, Fregni F, Martins Maia F, et al. rTMS treatment for depression in Parkinson's disease increases BOLD responses in the left prefrontal cortex. Int J Neuropsychopharmacol 2008;11: 173-183. (Pubitemid 351231826)
49. Fregni F, Santos CM, Myczkowski ML, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:1171-1174. (Pubitemid 39005779)
50. Epstein CM, Evatt ML, Funk A, et al. An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson's disease. Clin Neurophysiol 2007;118: 2189-2194. (Pubitemid 47386041)
51. Moellentine C, Rummans T, Ahlskog JE, et al. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci 1998;10:187-193.
52. van der Wurff FB, Stek ML, Hoogendijk WJ, Beekman AT. The efficacy and safety of ECT in depressed older adults: a literature review. Int J Geriatr Psychiatry 2003;18:894-904.
53. Ozer F, Meral H, Aydin B, Hanoglu L, Aydemir T, Oral T. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT 2005;21:125-127. (Pubitemid 40800041)
54. Dujardin K, Sockeel P, Devos D, et al. Characteristics of apathy in Parkinson's disease. Mov Disord 2007;22:778-784.
55. Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998;10:314-319.
56. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992;4:134-139.
57. Kirsch-Darrow L, Fernandez HH, Marsiske M, Okun MS, Bowers D. Dissociating apathy and depression in Parkinson disease. Neurology 2006;67:33-38. (Pubitemid 44305458)
58. Isella V, Melzi P, Grimaldi M, et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease. Mov Disord 2002;17:366-371. (Pubitemid 36041307)
59. Pluck GC, Brown RG. Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73:636-642.
60. Shulman LM. Apathy in patients with Parkinson's disease. Int Rev Psychiatry 2000;12:298-306.
61. Friedman J, Friedman HS. Fatigue in Parkinson's disease. Neurology 1993;43:2016-2018.
62. Friedman JH, Brown RG, Comella C, et al. Fatigue in Parkinson's disease: a review. Mov Disord 2007;22:297-308.
63. Herlofson K, Larsen JP. The influence of fatigue on healthrelated quality of life in patients with Parkinson's disease. Acta Neurol Scand 2003;107:1-6. (Pubitemid 36177324)
64. Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology 2004;63:1908-1911.
65. Lou JS, Kearns G, Oken B, Sexton G, Nutt J. Exacerbated physical fatigue and mental fatigue in Parkinson's disease. Mov Disord 2001;16:190-196. (Pubitemid 36049964)
66. Friedman JH, Chou KL. Sleep and fatigue in Parkinson's disease. Parkinsonism Relat Disord 2004;10(Suppl 1):S27-S35.
67. Rochester L, Hetherington V, Jones D, et al. Attending to the task: interference effects of functional tasks on walking in Parkinson's disease and the roles of cognition, depression, fatigue, and balance. Arch Phys Med Rehabil 2004;85:1578-1585. (Pubitemid 39349398)
68. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Nonrecognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002;8:193-197.
69. Marin RS. Differential diagnosis of apathy and related disorders of diminished motivation. Psychiatr Ann 1997;27:30-33.
70. Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry 1990;147:22-30.
71. Brown RG, Dittner A, Findley L, Wessely SC. The Parkinson fatigue scale. Parkinsonism Relat Disord 2005;11:49-55.
72. Martinez-Martin P, Catalan MJ, Benito-Leon J, et al. Impact of fatigue in Parkinson's disease: the fatigue impact scale for daily use (D-FIS). Qual Life Res 2006;15:597-606. (Pubitemid 43843968)
73. Zesiewicz TA, Patel-Larson A, Hauser RA, Sullivan KL. Social security disability insurance (SSDI) in Parkinson's disease. Disabil Rehabil 2007;29:1934-1936.
74. Karlsen K, Larsen JP, Tandberg E, Jorgensen K. Fatigue in patients with Parkinson's disease. Mov Disord 1999;14:237-241.
75. Leentjens AFG, Dujardin K, Marsh L, et al. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2008;23:2004-2014.
76. Dittner AJ, Wessely SC, Brown RG. The assessment of fatigue: a practical guide for clinicians and researchers. J Psychosom Res 2004;56:157-170. (Pubitemid 38317466)
77. Campbell JJ, Duffy JD. Treatment strategies in amotivated patients. Psychiatr Ann 1997;27:44-49.
78. Mendonca DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007;22:2070-2076.
79. Lou JS, Kearns G, Benice T, Oken B, Sexton G, Nutt J. Levodopa improves physical fatigue in Parkinson's disease: a doubleblind, placebo-controlled, crossover study. Mov Disord 2003;18: 1108-1114. (Pubitemid 37336933)
80. Schifitto G, Friedman JH, Oakes D, et al. Fatigue in levodopanaive subjects with Parkinson disease. Neurology 2008;71:481-485.
81. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003;18:287-293. (Pubitemid 36410825)
82. Ondo WG, Perkins T, Swick T, et al. Sodium oxybate for excessive daytime sleepiness in Parkinson's disease. An open-label polysomnographic study. Arch Neurol 2008;65:1337-1340.
83. Graham JM, Grunewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63: 434-440.
84. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003; 60:1756-1761. (Pubitemid 36737069)
85. Bronnick K, Aarsland D, Larsen JP. Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia. Acta Psychiatr Scand 2005;112:201-207. (Pubitemid 41176556)
86. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007;22:1061-1068.
87. Fernandez HH, Aarsland D, Fenelon G, et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov Disord 2008;23:484-500.
88. Onofrj M, Thomas A, Bonanni L. New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins. Expert Rev Neurother 2007;7:1731-1750. (Pubitemid 350260670)
89. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000;48:938-942. (Pubitemid 30637303)
90. Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord 2003;18:831-832. (Pubitemid 36939981)
91. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J med 1999;340:757-763.
92. Zahodne LB, Fernandez HH. Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective? CNS Spectr 2008;13(3 Suppl 4):26-33.
93. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006;CD003476.
94. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21:1899-1907. (Pubitemid 44848936)